Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PDL's McDade resigns

PDLI said Mark McDade will resign as CEO and a director by year end. The announcement came as the cardiovascular, cancer and autoimmune company said a three-month

Read the full 271 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE